GLP-1s Could Slow Cancer Growth, Says New Study
Similar content being viewed by others Introduction Type 2 diabetes is a global epidemic and a known independent risk factor for AKI and subsequent decline in kidney function 1,2,3
This drug promises significant results, as shown by the TRIUMPH-1 Phase 3 trial, where participants shed an average of 28.3% of body weight over 80 weeks
In Phase 2 trials, retatrutide, a GIP/GLP-1/glucagon based triple agonist, achieved a mean bodyweight reduction of up to 24.2% over 48 weeks
Stem Cells (2004) 22(5):84960.10.1634/stemcells.22-5-849 43 ShiYCWortonLEstebanLBaldockPFongCEismanJAet alEffects of continuous activation of vitamin D and Wnt response pathways on osteoblastic proliferation and differentiation
187 High-fiber diets may assist in weight control but have been shown to accelerate lumbar spine bone density loss in postmenopausal women, and bone mass often fails to recover even after weight regain